Highest-materiality recent filing
Safeguard Scientifics files Form 25 to voluntarily delist from Nasdaq, expects suspension Feb 12
Filed Form 25 with SEC on Feb 2, 2024 to voluntarily delist common stock from Nasdaq.
Safeguard Scientifics to voluntarily delist from Nasdaq on Feb 2, 2024; plans to deregister
Filed notice to delist common stock from Nasdaq via Form 25 on February 2, 2024.
Safeguard Scientifics sets Jan 12 for stock splits to enable going dark; names Mark Dow CEO/CFO
1-for-100 reverse split then 100-for-1 forward split effective Jan 12; trading on Nasdaq post-split Jan 16.
Safeguard Scientifics to delist from Nasdaq after 1-for-100 reverse split; special dividend $0.35
Shareholders approved reverse stock split 1-for-100 followed by forward split 100-for-1 to reduce record holders below 300.
Special cash dividend of $0.35 per share, payable Dec 28 to holders of record Dec 19.
Safeguard Scientifics Q3 net income $0.9M, vs loss $3.2M; cash $15.7M
Q3 net income $0.9M ($0.06 diluted EPS) vs net loss $3.2M ($0.19 loss) in Q3 2022.
Safeguard Scientifics board approves plan to go private via stock splits, delist from Nasdaq
Reverse stock split (1:50 to 1:100) followed by forward split; small holders cashed out at $1.65/share.
Safeguard Scientifics Q2 2023 net loss of $2.9M; six portfolio co. revenue up 12.8%
Net loss Q2 2023 of $2.9M ($0.18/sh) vs net income $0.5M ($0.03/sh) in Q2 2022.
Safeguard Scientifics posts FY2022 net loss of $14.3M vs net income of $27.0M in 2021
Net loss Q4 2022 $4.9M ($0.30/share) vs loss $8.6M ($0.51) in Q4 2021; FY2022 net loss $14.3M ($0.87) vs net income $27.0M ($1.36) in FY2021.
Safeguard Scientifics Q3 2022 net loss $3.2M vs prior-year net income $18.3M
Received $5.3M initial cash proceeds from Lumesis acquisition, recording a gain of $4.7M.
Safeguard Scientifics exits Lumesis via sale to SOLVE Advisors for $5.3M initial cash
Safeguard received $5.3M initial cash proceeds from sale of Lumesis stake to SOLVE Advisors.
Net income of $0.5M ($0.03/diluted EPS) vs net loss of $0.3M ($0.02 loss/share) in Q2 2021.
Safeguard Scientifics Q1 net loss $6.7M; strategic review with Houlihan Lokey continues
Net loss $6.7M ($0.40 per share) vs net income $17.6M ($0.84 per share) in Q1 2021.
Safeguard Scientifics reports $60.8M cash proceeds from 2021 exits; initiates strategic review
Repurchased 4.5M shares in 2021, including 4.3M via Dutch auction at $9.06 per share.
Safeguard posts Q3 net income of $18.3M ($0.88 per share); completes $38.7M self-tender
Repurchased 4.3M shares for $38.7M via modified Dutch auction self-tender completed Oct 7, 2021.
Completed sale of Flashtalking interest for ~$44.8M cash; up to $0.8M additional from escrow over 24 months.
Safeguard Scientifics Q2 net loss narrows to $0.3M; expects $43M from Flashtalking sale
Net loss of $0.3M ($0.02 per share) vs loss of $9.9M ($0.48) in Q2 2020; improvement driven by $9.2M in gains.
Safeguard Scientifics announces Flashtalking acquisition by Mediaocean; expects $43M cash
Flashtalking, a Safeguard portfolio company, signed definitive agreement to be acquired by Mediaocean.
the Board appointed Mark Dow of Rock Creek as the Company’s Chief Executive Officer, Chief Financial Officer and Secretary effective as of January 1, 2024.
Messrs. Salzman and Herndon will no longer serve as the Company’s executive officers as of December 31, 2023
Messrs. Salzman and Herndon will no longer serve as the Company’s executive officers as of December 31, 2023
Ross D. DeMont and Beth S. Michelson were elected as directors of the Company
Ross D. DeMont and Beth S. Michelson were elected as directors of the Company
Max materiality 0.85 · Median 0.60 · Most common event earnings